Shopping Cart
Remove All
Your shopping cart is currently empty
CDK5-IN-4 (compound 4), a potent type-II multikinase inhibitor, targets CDK5 with an IC 50 of 9.8 μM. Additionally, it inhibits GSK-3α, GSK-3β, CDK9, and CDK2, demonstrating IC 50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. This compound is applicable in glioblastoma research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $1,980 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $2,500 | 8-10 weeks | 8-10 weeks |
| Description | CDK5-IN-4 (compound 4), a potent type-II multikinase inhibitor, targets CDK5 with an IC 50 of 9.8 μM. Additionally, it inhibits GSK-3α, GSK-3β, CDK9, and CDK2, demonstrating IC 50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. This compound is applicable in glioblastoma research. |
| Targets&IC50 | GSK-3α:0.98 ± 0.0 μM, GSK-3β:4.00 ± 1.3 μM, CDK9:1.76 ± 0.3 μM, CDK2:6.24 ± 2.8 μM, CDK5:9.8 ± 2.29 μM |
| Molecular Weight | 449.48 |
| Formula | C24H24FN5O3 |
| Cas No. | 1212711-91-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.